Literature DB >> 21311988

The cystic fibrosis neutrophil: a specialized yet potentially defective cell.

Elaine Hayes1, Kerstin Pohl, Noel G McElvaney, Emer P Reeves.   

Abstract

Cystic fibrosis (CF) is one of the commonest genetically inherited diseases in the world. It is characterized by recurrent respiratory tract infections eventually leading to respiratory failure. One of the hallmarks of this disease is a persistent and predominantly neutrophil driven inflammation. Neutrophils provide the first line of defence by killing and digesting phagocytosed bacteria and fungi, yet despite advances in our understanding of the molecular and cellular basis of CF, there remains a paradox of why recruited CF neutrophils fail to eradicate bacterial infections in the lung. This review describes mechanisms involved in neutrophil migration, microbial killing and apoptosis leading to inflammatory resolution. We discuss dysregulated neutrophil activity and consider genetic versus inflammatory neutrophil reprogramming in CF and ultimately pharmacological modulation of the CF neutrophil for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21311988     DOI: 10.1007/s00005-011-0113-6

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  34 in total

Review 1.  Update in Cystic Fibrosis 2018.

Authors:  Bonnie W Ramsey; Gregory P Downey; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

2.  Novel cellular targets of AhR underlie alterations in neutrophilic inflammation and inducible nitric oxide synthase expression during influenza virus infection.

Authors:  Jennifer L Head Wheeler; Kyle C Martin; B Paige Lawrence
Journal:  J Immunol       Date:  2012-12-10       Impact factor: 5.422

Review 3.  Neutrophils at work.

Authors:  William M Nauseef; Niels Borregaard
Journal:  Nat Immunol       Date:  2014-07       Impact factor: 25.606

Review 4.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

5.  Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis.

Authors:  Adèle Coriati; Chantal Massé; Aurélie Ménard; Guillaume F Bouvet; Yves Berthiaume
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

6.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

7.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

8.  Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils.

Authors:  Yun Zhou; Kejing Song; Richard G Painter; Martha Aiken; Jakob Reiser; Bruce A Stanton; William M Nauseef; Guoshun Wang
Journal:  J Innate Immun       Date:  2013-03-06       Impact factor: 7.349

Review 9.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

10.  Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung.

Authors:  Isabel Vega-Carrascal; David A Bergin; Oliver J McElvaney; Cormac McCarthy; Nessa Banville; Kerstin Pohl; Mitsuomi Hirashima; Vijay K Kuchroo; Emer P Reeves; Noel G McElvaney
Journal:  J Immunol       Date:  2014-01-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.